Search Results - "Lopez-Rios F"

204P Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey.

Authors: Paredes, R. Lopez-Rios, F. Moore, A. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS298-S299. 2p.

Reply to comment by Normanno et al on 'A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens'.

Authors: de Castro, D G Lopez-Rios, F

Source: British Journal of Cancer. 11/6/2012, Vol. 107 Issue 10, p1793-1794. 2p.

Effect of an acceptance and commitment group therapy in the treatment of panic disorder and agoraphobia. A preliminary study.

Authors: Leon-quismondo, L. Lopez-rios, F. Rodriguez-pedraza, E. et al.

Source: European Psychiatry. Mar2016 Supplement, Vol. 33, pS277-S277. 1p.

O-078 Gene expression profiling of malignant mesothelioma forprognostic prediction and identification of potential therapeutic targets and differential diagnostic markers

Authors: Lopez-Rios, F. Chuai, S. Hussain, S. et al.

Source: Lung Cancer (01695002). Jul2005 Supplement 2, Vol. 49, pS29-S29. 1p.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Authors: Alvarez, R Musteanu, M Garcia-Garcia, E et al.

Source: British Journal of Cancer. 8/20/2013, Vol. 109 Issue 4, p926-933. 8p. 1 Chart, 4 Graphs.

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens.

Authors: Gonzalez de Castro, D Angulo, B Gomez, B et al.

Source: British Journal of Cancer. 7/10/2012, Vol. 107 Issue 2, p345-351. 7p.

Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer.

Authors: Carretero, J. Medina, P. P. Blanco, R. et al.

Source: Oncogene. 3/8/2007, Vol. 26 Issue 11, p1616-1625. 10p.

1982P Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC).

Authors: Perez Valderrama, B. Garcia Del Muro, X. Merseburger, A.S. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1146-S1147. 2p.

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

Authors: Alvarez, R Musteanu, M Garcia-Garcia, E et al.

Source: British Journal of Cancer. 10/14/2014, Vol. 111 Issue 8, p1677-1678. 2p.

12P Molecular features of KRAS mutant NSCLC: Weaving a future score for immune-checkpoint inhibitors (ICI).

Authors: Dorta Suarez, M. Jimenez Munarriz, B. Del Barrio, A. et al.

Source: Annals of Oncology. 2021 Supplement 6, Vol. 32, pS1349-S1349. 1p.

748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study.

Authors: Bamias, A. Merseburger, A. Loriot, Y. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS581-S581. 1p.

604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer.

Authors: Leyvraz, S. Yang, J.C-H. Casali, P.G. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS503-S503. 1p.

1833PDLack of efficiency of precision oncology with target-based investigational treatments for patients in early phase clinical trials based on pre-screened molecular alterations.

Authors: Spéville, B Doger de Moreno, V Hernandez, T et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER).

Authors: Fernandez, M. Calvo, I. Martinez, N. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p396-397. 2p.

Molecular effects of lapatinib in HER2 positive ductal carcinoma in situ (DCIS).

Authors: Estevez, L. G. Suarez, A. Calvo, I. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p1647-1647. 1p.

PP 28 Analytical performance and workflow comparison study of three methods for detecting KRAS mutations in formalin-fixed paraffin-embedded tissue (FFPET) specimens of colorectal cancer (CRC)

Authors: de Castro, D. Gonzalez Angulo, B. Gomez, B. et al.

Source: European Journal of Cancer. Oct2011 Supplement 4, Vol. 47, pS18-S18. 1p.

6139 POSTER Incidence of VEGFR-2, PDGFRa and PDGFRβ Mutations in Colorectal Cancer and Potential Value as Prognostic Markers

Authors: Garcia, P. Estevez Castafio, A. Martin, A.C. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS434-S434. 1p.

O-013 Global expression profiling of lung primary tumors: Correlationwith pathological and genetic characteristics

Authors: Angulo, B. Conde, E. Tang, M. et al.

Source: Lung Cancer (01695002). Jul2005 Supplement 2, Vol. 49, pS8-S8. 1p.

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Authors: Peters S Meyer ML André F et al.

Source: ESMO open [ESMO Open] 2026 Jul 10; Vol. 11 (8), pp. 108316. Date of Electronic Publication: 2026 Jul 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.

Authors: Hofman V Rignol G Mograbi B et al.

Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Aug; Vol. 218, pp. 109507. Date of Electronic Publication: 2026 Jun 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE